Journal article icon

Journal article

Mutant mice with calcium-sensing receptor (CaSR) activation have hyperglycemia, that is rectified by calcilytic therapy

Abstract:
The calcium-sensing receptor (CaSR) is a family C G-protein-coupled receptor (GPCR) that plays a pivotal role in extracellular calcium homeostasis. The CaSR is also highly expressed in pancreatic islet α- and β-cells that secrete glucagon and insulin, respectively. To determine whether the CaSR may influence systemic glucose homeostasis, we characterized a mouse model with a germline gain-of-function CaSR mutation, Leu723Gln, referred to as Nuclear flecks (Nuf). Heterozygous- (CasrNuf/+) and homozygous-affected (CasrNuf/Nuf) mice were shown to have hypocalcemia in association with impaired glucose tolerance and insulin secretion. Oral administration of a CaSR antagonist compound, known as a calcilytic, rectified the glucose intolerance and hypoinsulinemia of CasrNuf/+ mice, and ameliorated glucose intolerance in CasrNuf/Nuf mice. Ex vivo studies showed CasrNuf/+ and CasrNuf/Nuf mice to have reduced pancreatic islet mass and β-cell proliferation. Electrophysiological analysis of isolated CasrNuf/Nuf islets showed CaSR activation to increase the basal electrical activity of β-cells independently of effects on the activity of the ATP-sensitive K+ (KATP) channel. CasrNuf/Nuf mice also had impaired glucose-mediated suppression of glucagon secretion, which was associated with increased numbers of α-cells and a higher α-cell proliferation rate. Moreover, CasrNuf/Nuf islet electrophysiology demonstrated an impairment of α-cell membrane depolarization in association with attenuated α-cell basal KATP channel activity. These studies indicate that the CaSR activation impairs glucose tolerance by a combination of α- and β-cell defects and also influences pancreatic islet mass. Moreover, our findings highlight a potential application of targeted CaSR compounds for modulating glucose metabolism.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1210/en.2017-00111

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
RDM
Sub department:
OCDEM
Role:
Author


More from this funder
Funding agency for:
Thakker, R
Hannan, F
Grant:
FP7-264663
G1000467
More from this funder
Funding agency for:
Rorsman, P
Thakker, R
Grant:
FP7-264663
More from this funder
Funding agency for:
Kallay, E
Thakker, R
Grant:
FP7-264663
FP7-264663
More from this funder
Funding agency for:
Nesbit, M
Thakker, R
Grant:
G1000467
FP7-264663
More from this funder
Funding agency for:
Nesbit, M
Stewart, M
Wells, S
Cox, R
Hannan, F
Hugill, A
Bentley, L
Hough, T
Thakker, R
Joynson, E
Grant:
G1000467
MC_U142661184
MC_U142661184
MC_U142661184
G1000467
MC_U142661184
MC_U142661184
MC_U142661184
FP7-264663
MC_U142661184


Publisher:
Oxford University Press
Journal:
Endocrinology More from this journal
Volume:
158
Issue:
8
Pages:
2486-2502
Publication date:
2017-06-02
Acceptance date:
2017-05-30
DOI:
EISSN:
1945-7170
ISSN:
0013-7227


Language:
English
Keywords:
Pubs id:
pubs:698624
UUID:
uuid:8041bf03-4ac7-4faf-85dc-f9866b894bb5
Local pid:
pubs:698624
Source identifiers:
698624
Deposit date:
2017-06-20

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP